Why Bristol?
- £150m funding raised ...
... by Eng Bio spinout companies
- £300m partnership ...
... to incubate startup businesses
- 17 active spinouts...
... in Eng Bio from the University of Bristol
The evotype: placing evolution at the forefront of engineered biology
Evolution is inevitable. It is the bedrock of being, and of biology. Research teams the world over have been undone by its inclination, but now a framework is emerging to place evolution right at the heart of bioengineering research.
How a Bristol diabetes discovery created a deep tech ecosystem
Thirty years of synthetic chemistry research has culminated in a major breakthrough in our ability to bind glucose. With support from a leading global healthcare company and Bristol's local spinout ecosystem this work is being translated into new treatments and technologies that could revolutionise the way we manage diabetes.

Social research in action
WORLD FIRST: Bristol Launches AMR Conflict and Security Community
Engineering biology is transforming the fight against antimicrobial resistance, yet war and conflict is threatening progress. In response, the University of Bristol is leading a charge to bring together world leading experts in AMR, engineering biology and security to drive new strategy, research and coordinated global action.
On a mission to cure chronic disease. With AI.
Former Bristol postdoctoral fellow Elisa Pedone is a biomedical scientist with a decade of experience in stem and cancer biology, microfluidics, live-cell imaging and AI-enabled quality control. Her research was central to the establishment of CellVoyant, a University of Bristol AI-first biotechnology spinout. Now, continuing her work alongside CEO and founder, Rafael Carazo Salas, Elisa and the wider Cellvoyant team have launched an innovative AI platform that instantly predicts cell states, transforming how patients will benefit from life-changing cell-based therapies.

Making change possible
not needed
Find out more about Engineering Biology at Bristol
